GlassScriptPhysician profile
Paul J Corsi
NPI 1275573461
$6,848.39
in general payments reported to CMS, 2019-2025
30 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $424 · 2020: $79.73 · 2021: $298 · 2022: $345 · 2023: $4,826 · 2024: $551 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,920 · Food and Beverage: $1,782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,920.00 |
| Food and Beverage | $1,782.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $4,059.05 | 2023 | Myrisk |
| Abbvie INC. | $445.13 | 2019-2025 | Liletta, Lo Loestrin Fe, Orilissa |
| Hologic Sales and Service, LLC | $309.56 | 2019-2025 | Coolseal Generator, Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $270.59 | 2023-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $164.96 | 2021-2025 | |
| Biogen, INC. | $156.02 | 2024-2025 | Zurzuvae |
| Gynesonics, INC. | $153.15 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Aspira Women'S Health INC | $130.32 | 2020-2022 | |
| Pfizer INC. | $126.48 | 2019-2023 | |
| Millicent US INC | $113.77 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Ethicon US, LLC | $101.88 | 2019-2022 | |
| Coopersurgical, INC. | $73.99 | 2021-2024 | Paragard T 380a |
| Exeltis, USA INC. | $73.53 | 2021-2025 | Slynd |
| Amgen INC. | $64.87 | 2019-2023 | Evenity, Prolia |
| Therapeuticsmd, INC. | $64.59 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $60.67 | 2021-2022 | |
| Smith+Nephew, INC. | $60.49 | 2023-2024 | Stravix Pl, Grafix Pl, Pico 7 |
| Exact Sciences Corporation | $58.69 | 2023-2024 | Cologuard Collection Kit |
| Lupin INC. | $51.13 | 2019-2020 | |
| Organon LLC | $46.14 | 2023-2024 | Nexplanon |
| Myovant Sciences INC. | $41.37 | 2022 | |
| Axonics, INC. | $39.51 | 2024 | Axonics |
| Sumitomo Pharma America, INC. | $38.34 | 2023 | Myfembree |
| Coloplast Corp | $30.47 | 2024 | |
| Becton, Dickinson and Company | $21.36 | 2024 | Bd Onclarity |
| Bayer Healthcare Pharmaceuticals INC. | $20.74 | 2023 | |
| Medicem INC. | $20.10 | 2023 | |
| Shield Therapeutics INC | $18.97 | 2024 | |
| Allergan, INC. | $16.72 | 2020 | |
| Duchesnay USA Incorporated | $15.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Corsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.